HIF prolyl hydroxylase inhibitors for anemia

Expert Opinion on Investigational Drugs

Volumn 20, Issue 5, 2011, Pages 645-656

  Muchnik, Eugene ^a   Kaplan, Joshua ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

anemia; anemia drug therapy; hypoxia inducible factor; ischemia reperfusion therapy; neoplasia drug therapy; oxygen physiology; prolyl hydroxylase

Indexed keywords

AKB 6548; COBALT; DEFEROXAMINE; ENZYME INHIBITOR; FG 2216; FG 4592; GSK 1278863A; HYPOXIA INDUCIBLE FACTOR; ISOPROTEIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PROLYLHYDROXYLASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANEMIA; CHRONIC KIDNEY DISEASE; HUMAN; IRON DEFICIENCY ANEMIA; NONHUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW;

ANEMIA; ANIMALS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; PROCOLLAGEN-PROLINE DIOXYGENASE;

EID: 79953649414     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.566861     Document Type: Review

References (116)

1. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992;20:5447-54
2. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230-7
3. Jaakkola P, Mole DR, Tian Y-M, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292:468-72 (Pubitemid 32335942)
4. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292:464-7
5. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5 (Pubitemid 29246458)
6. Lando D, Peet DJ, Whelan DA, et al. Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science 2002;295:858-61 (Pubitemid 34118367)
7. Hewitson KS, McNeill LA, Riordan MV, et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem 2002;277:26351-5 (Pubitemid 34967127)
8. Lando D, Peet DJ, Gorman JJ, et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 2002;16:1466-71 (Pubitemid 34686328)
9. Ehrismann D, Flashman E, Genn DN, et al. Studies on the activity of the hypoxia-inducible-factor hydroxylases using an oxygen consumption assay. Biochem J 2007;401:227-34 (Pubitemid 46114616)
10. Page EL, Chan DA, Giaccia AJ, et al. Hypoxia-inducible factor-1alpha stabilization in non-hypoxic conditions: role of oxidation and intracellular ascorbate depletion. Mol Biol Cell 2008;19:86-94 (Pubitemid 351186135)
11. Selak MA, Armour SM, MacKenzie ED, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005;7:77-85 (Pubitemid 40126384)
12. Isaacs JS, Jung YJ, Mole DR, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005;8:143-53 (Pubitemid 41132743)
13. Ratcliffe PJ. HIF-1 and HIF-2: working alone or together in hypoxia? J Clin Invest 2007;117:862-5 Review of the complementary but separate actions of HIF-1 and HIF-2.
14. Makino Y, Cao R, Svensson K, et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001;414:550-4 (Pubitemid 33131538)
15. Makino Y, Kanopka A, Wilson WJ, et al. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. J Biol Chem 2002;277:32405-8 (Pubitemid 34984738)
16. Ortiz-Barahona A, Villar D, Pescador N, et al. Genome-wide identification of hypoxia-inducible factor binding sites and target genes by a probabilistic model integrating transcription-profiling data and in silico binding site prediction. Nucleic Acids Res 2010;38:2332-45
17. Gruber M, Hu CJ, Johnson RS, et al. Acute postnatal ablation of Hif-2- results in anemia. Proc Natl Acad Sci USA 2007;104:2301-6 (Pubitemid 46391392)
18. Scortegagna M, Ding K, Zhang Q, et al. HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood 2005;105:3133-40
19. Paliege A, Rosenberger C, Bondke A, et al. Hypoxia-inducible factor-2alpha-expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible factor stabilization. Kidney Int 2010;77:312-18
20. Furlow PW, Percy MJ, Sutherland S, et al. Erythrocytosis-associated HIF-2-mutations demonstrate a critical role for residues C-terminal to the hydroxylacceptor proline. J Biol Chem 2009;284:9050-8
21. Gale DP, Harten SK, Reid CD, et al. Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2alpha mutation. Blood 2008;112:919-21
22. Martini M, Teofili L, Cenci T, et al. A novel heterozygous HIF2alpha M535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis. Haematologica 2008;93:1068-71 (Pubitemid 351957024)
23. Percy MJ, Furlow PW, Lucas GS, et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med 2008;358:162-8
24. van Wijk R, Sutherland S, Van Wesel AC, et al. Erythrocytosis associated with a novel missense mutation in the HIF2A gene. Haematologica 2010;95(5):829-32
25. Bosch-Marce M, Okuyama H, Wesley JB, et al. Effects of aging and hypoxia inducible factor 1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia. Circ Res 2007;101:1310-18 (Pubitemid 350294648)
26. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004;10:858-64 (Pubitemid 39070860)
27. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-13 (Pubitemid 26272112)
28. Simon MP, Tournaire R, Pouyssegur J. The angiopoietin-2 gene of endothelial cells is up-regulated in hypoxia by a HIF binding site located in its first intron and by the central factors GATA-2 and Ets-1. J Cell Physiol 2008;217:809-18
29. Fukuda R, Zhang H, Kim JW, et al. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 2007;129:111-22 (Pubitemid 46507584)
30. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006;3:177-85
31. Iyer NV, Kotch LE, Agani F, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1alpha. Genes Dev 1998;12:149-62 (Pubitemid 28060446)
32. Seagroves TN, Ryan HE, Lu H, et al. Transcription factor HIF-1 is a necessary mediator of the Pasteur effect in mammalian cells. Mol Cell Biol 2001;21:3436-44 (Pubitemid 32381779)
33. Semenza GL, Jiang BH, Leung SW, et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia inducible factor 1. J Biol Chem 1996;271:32529-37
34. Kapitsinou PP, Liu Q, Unger TL, et al. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood 2010;116:3039-48
35. Shah YM, Matsubara T, Ito S, et al. Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. Cell Metab 2009;9:152-64
36. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007;117:1926-32 Paper discusses some of the key effects of HIF on iron regulation.
37. Rolfs A, Kvietikova I, Gassmann M, Wenger RH. Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1. J Biol Chem 1997;272:20055-62 (Pubitemid 27340110)
38. Lok CN, Ponka P. Identification of a hypoxia response element in the transferrin gene. J Biol Chem 1999;274:24147-52
39. Tacchini L, Bianchi L, Bernelli-Zazzera A, Cairo G. Transferrin receptor induction by hypoxia: HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. J Biol Chem 1999;274:24142-6
40. Mukhopadhyay CK, Mazumder B, Fox PL. Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency. J Biol Chem 2000;275:21048-54 (Pubitemid 30481794)
41. Liu YL, Ang SO, Weigent DA, et al. Regulation of ferrochelatase gene expression by hypoxia. Life Sci 2004;75:2035-43 (Pubitemid 39092991)
42. Mastrogiannaki M, Matak P, Keith B, et al. HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. J Clin Invest 2009;119:1159-66
43. McMahon S, Grondin F, McDonald PP, et al. Hypoxia-enhanced expression of the proprotein convertase furin is mediated by hypoxia-inducible factor-1: impact on the bioactivation of proproteins. J Biol Chem 2005;280:6561-9 (Pubitemid 40341206)
44. Silvestri L, Pagani A, Camaschella C. Furin mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood 2007;109:4503-10
45. Lieb ME, Menzies K, Moschella MC, et al. Mammalian EGLN genes have distinct patterns of mRNA expression and regulation. Biochem Cell Biol 2002;80:421-6 (Pubitemid 35365999)
46. Berra E, Benizri E, Ginouves A, et al. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1a in normoxia. EMBO J 2003;22:4082-90 (Pubitemid 37021737)
47. Appelhoff RJ, Tian YM, Raval RR, et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 2004;279:38458-65 (Pubitemid 39295997)
48. Aragones J, Schneider M, Van Geyte K, et al. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet 2008;40:170-80 (Pubitemid 351171394)
49. Takeda K, Cowan A, Fong GH. Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation 2007;116:774-81 (Pubitemid 47255995)
50. Takeda K, Aguila HL, Parikh NS, et al. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood 2008;111:3229-35 Paper describes phenotype of different PHD knockout mouse models.
51. Minamishima YA, Moslehi J, Bardeesy N, et al. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood 2008;111:3236-44
52. Bishop T, Gallagher D, Pascual A, et al. Abnormal sympathoadrenal development and systemic hypotension in PHD3 mice. Mol Cell Biol 2008;28:3386-400 (Pubitemid 351657101)
53. Choudhury R, Hardy A, Schofield CJ. The human oxygen sensing machinery and its manipulation. Chem Soc Rev 2008;37:1308-19
54. Cockman ME, Webb JD, Kramer HB, et al. Proteomics-based identification of novel factor inhibiting hypoxia-inducible factor (FIH) substrates indicates widespread asparaginyl hydroxylation of ankyrin repeat domain-containing proteins. Mol Cell Proteomics 2009;8:535-46
55. Coleman ML, McDonough MA, Hewitson KS, et al. Asparaginyl hydroxylation of the Notch ankyrin repeat domain by factor inhibiting hypoxia-inducible factor. J Biol Chem 2007;282:24027-38 (Pubitemid 47328043)
56. Zheng X, Linke S, Dias JM, et al. Interaction with factor inhibiting HIF-1 defines an additional mode of cross-coupling between the Notch and hypoxia signaling pathways. Proc Natl Acad Sci USA 2008;105:3368-73 (Pubitemid 351723559)
57. Zhang N, Fu Z, Linke S, et al. The asparaginyl hydroxylase factor inhibiting HIF-1alpha is an essential regulator of metabolism. Cell Metab 2010;11:364-78
58. Linehan WM, Lerman MI, Zbar B. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA 1995;273:564-70
59. Ang SO, Chen H, Hirota K, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 2002;32(4):614-21 (Pubitemid 35435173)
60. van Wijk R, Sutherland S, Van Weset ACW, et al. Erythrocytosis associated with a novel missense mutation in the HIF2A gene. Haematologica 2010;95(5):829-32
61. Percy MJ, Zhao Q, Flores A, et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci USA 2006;103(3):654-9 (Pubitemid 43153081)
62. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA binding activity: Implications for models of hypoxia signal transduction. Blood 1993;82:3610-5 (Pubitemid 24006041)
63. Heimpel H. Stimulation of hemopoiesis in aplastic anemia. Haematol Blood Transfus 1979;24:129-37
64. Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 1988;242:1412-5
65. McDonoguh MA, McNeill LA, Tilliet M, et al. Selective inhibition of factor inhibiting hypoxia-inducible factor. J Am Chem Soc 2005;127:7680-1 (Pubitemid 40745948)
66. Schlemminger I, Mole DR, McNeill LA, et al. Analogues of dealanylalahopcin are inhibitors of human HIF prolyl hydroxylases. Bioorg Med Chem Lett 2003;13:1451-4 (Pubitemid 36369187)
67. Warshakoon NC, Wu S, Boyer A, et al. A novel series of imidazo[1,2-a] pyridine derivates as HIF-1alpha prolyl hydroxylase inhibitors. Bioorg Med Chem Lett 2006;16:5598-601
68. Murray JK, Balan C, Allgeier AM, et al. Dipeptidyl-quinolone derivatives inhibit hypoxia inducible factor-1alpha prolyl hydroxylases-1, -2, and --3 with altered selectivity. J Comb Chem 2011. [Epub ahead of print]
69. Lienard BM, Conejo-Garcia A, Stolze I, et al. Evaluation of aspirin metabolites as inhibitors of hypoxia-inducible factor hydroxylases. Chem Commun 2008;47:6393-5
70. Rajagopalan S, Olin J, Deitcher S, et al. Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience. Circulation 2007;115(10):1234-43 (Pubitemid 46594767)
71. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987;316(2):73-8 (Pubitemid 17052741)
72. Silberberg J, Racine N, Barre P, Sniderman AD. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 1990;6:1-4 (Pubitemid 20132367)
73. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 1990;300(6724):573-8
74. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90 (Pubitemid 28385655)
75. Drueke TB, Locatelli F, Clyne N, et al.; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-84 (Pubitemid 44749316)
76. Singh AK, Szczech L, Tang KL, et al.; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98 (Pubitemid 44749317)
77. Pfeffer MA, Burdmann EA, Chen CY, et al.; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-32
78. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008;74(6):791-8 A thought-provoking post hoc analysis of an important trial of the effects of erythropoietin analogs.
79. Valeri CR, Cassidy G, Pivacek LE, et al. Anemia-induced increase in the bleeding time: implications for treatment of nonsurgical blood loss. Transfusion 2001;41:977-83 (Pubitemid 33642786)
80. Kwaan HC, Wang J. Hyperviscosity in polycythemia vera and other red cell abnormalities. Semin Thromb Hemost 2003;29:451-8 (Pubitemid 37352644)
81. Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000;95:2983-89 (Pubitemid 30235913)
82. Kirkeby A, Torup L, Bochsen L, et al. High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO). Thromb Haemost 2008;99:720-8 (Pubitemid 351694228)
83. Patel TV, Mittal BV, Keithi-Reddy SR, et al. Endothelial activation markers in anemic nondialysis chronic kidney disease patients. Nephron Clin Pract 2008;110:c244-50
84. Brines M. The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: a tale of two receptors. Blood Purif 2010;29:86-92
85. Kanbay M, Perazzella MA, Kasapoglu B, et al. Erythropoiesis stimulatory agent-resistant anemia in dialysis patients: review of causes and management. Blood Purif 2010;29:1-12
86. Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology 2007;12:321-30
87. Nemeth E. Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias. Adv Hematol 2009. [Epub ahead of print]
88. Valore EV, Ganz T. Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin. Blood Cells Mol Dis 2008;40:132-8 (Pubitemid 350192311)
89. Mole DR. Iron homeostasis and its interaction with prolyl hydroxylases. Antioxid Redox Signal 2010;12(4):445-58 Excellent review of HIF and iron homeostasis.
90. Klaus S, Langsetmo I, Neff T, et al. Beneficial pharmacodynamic effects resulting from "complete erythropoiesis" induced by novel HIF prolyl hydroxylase inhibitors FG-2216 and FG-4592. J Am Soc Nephrol 2008;19:524A
91. Besarab A, Hulter HN, Klaus S, et al. FG-4592, a novel oral HIF prolyl hydroxylase inhibitor (HIF-PHI), elevates hemoglobin in anemic stage 3-4 CKD patients. J Am Soc Nephrol 2010;21:95A
92. Bernhardt WM, Wiesener MS, Scigalla P, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 2010;21:2151-6
93. Provenzano R, Fadda G, Bernardo M, et al. FG-2216, A novel oral HIF-PHI, stimulates erythropoiesis and increases hemoglobin concentration in patients with non-dialysis CKD. Am J Kidney Dis 2008;51(4):B80
94. Frohna PA, Milwee S, Pinkett J, et al. Preliminary results from a randomized, single-blind, placebo-controlled trial of FG-4592, a novel hypoxia inducible factor prolyl hydroxylase inhibitor, in subjects with CKD anemia. J Am Soc Nephrol 2007;18:515A
95. Maynard MA, Ohh M. The role of hypoxia-inducible factors in cancer. Cell Mol Life Sci 2007;64(16):2170-80 (Pubitemid 350103108)
96. Chan DA, Giaccia AJ. PHD2 in tumour angiogenesis. Br J Cancer 2010;103(1):1-5
97. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008;15(4):678-85 (Pubitemid 351405072)
98. Podar K, Anderson KC. A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways. Cell Cycle 2010;9(9):1722-8
99. Seeley TW, Sternlicht MD, Stephenson R, et al. HIF prolyl hydroxylase inhibitors increase erythropoiesis without promotion of tumor progression in the presence or absence of concomitant chemotherapy [abstract 364]. Keystone Symposium Molecular, Cellular, Physiological and Pathogenic Responses of Hypoxia; 2008
100. Seeley TW, Langsetmo I, Stephenson R, et al. FG2216: tumor progression studies and correction of anemia of chronic disease in xenograft models. J Am Soc Nephrol 2005;16:481A
101. Zhang Q, Gu J, Li L, et al. Control of Cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell 2009;16:1-12
102. Natarajan R, Salloum FN, Fisher BJ, et al. Hypoxia inducible factor-1 upregulates adiponectin in diabetic mouse hearts and attenuates post-ischemic injury. J Cardiovasc Pharmacol 2008;51:178-87 (Pubitemid 351301479)
103. Hyvarinen J, Hassinen IE, Sormunen R, et al. Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury. J Biol Chem 2010;285:13646-57
104. Bao W, Qin P, Needle S, et al. Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat. J Cardiovasc Pharmacol 2010;56(2):147-55
105. Kilian EG, Sadoni S, Vicol C, et al. Myocardial transfection of hypoxia inducible factor-1alpha via an adenoviral vector during coronary artery bypass grafting - a multicenter phase I and safety study. Circ J 2010;74(5):916-24
106. Harten SK, Ashcroft M, Maxwell PH. Prolyl hydroxylase domain inhibitors: a route to HIF activation and neuroprotection. Antioxid Redox Signal 2010;12(4):459-80
107. Niatsetskaya Z, Basso M, Speer RE, et al. HIF prolyl hydroxylase inhibitors prevent neuronal death induced by mitochondrial toxins: therapeutic implications for Huntington's disease and Alzheimer's disease. Antioxid Redox Signal 2010;12(4):435-43
108. Weidemann A, Bernhardt WM, Klanke B, et al. HIF activation protects from acute kidney injury. J Am Soc Nephrol 2008;19:486-94 (Pubitemid 351355392)
109. Bernhardt WM, Campean V, Kany S, et al. Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure. J Am Soc Nephrol 2006;17(7):1970-8 (Pubitemid 44036181)
110. Amador A, Grande L, Marti J, et al. Ischemic pre-conditioning in deceased donor liver transplantation: a prospective randomized clinical trial. Am J Transplant 2007;7(9):2180-9 (Pubitemid 47247061)
111. Cantley J, Selman C, Shukla D, et al. Deletion of the von hippel-Linday gene in pancreatic beta cells impairs glucose homeostasis in mice. J Clin Invest 2009;119:125-35
112. Cheng K, Ho K, Stokes R, et al. Hypoxia-inducible factor-1alpha regulates beta cell function in mouse and human islets. J Clin Invest 2010;120:2171-83
113. Shimoda LA, Semenza GL. HIF and the lung - role of hypoxia-inducible factors in pulmonary development and disease. Am J Respir Crit Care Med 2011;183:152-6
114. Farha S, Asosingh K, Xu W, et al. Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities. Blood 2011. [Epub ahead of print]
115. Yu AY, Shimoda LA, Iyer NV, et al. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. J Clin Invest 1999;103:691-6 (Pubitemid 29122422)
116. Brusselmans K, Compernolle V, Tjwa M, et al. Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J Clin Invest 2003;111:1519-27 (Pubitemid 38063284)